Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$38.75 USD

38.75
1,430,322

-0.41 (-1.05%)

Updated Jul 15, 2024 02:01 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

by Zacks Equity Research

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.

GSK's Jemperli Effective Against First-Line Endometrial Cancer

by Zacks Equity Research

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $35.04 in the latest trading session, marking a +1.92% move from the prior day.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%

by Zacks Equity Research

Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.

GSK (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $35.05, marking a +0.34% move from the previous day.

Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?

by Zacks Equity Research

Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.

Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More

by Zacks Equity Research

Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.

GSK (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $33.72, moving +0.6% from the previous trading session.

GSK (GSK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $33.59 in the latest trading session, marking a -1.29% move from the prior day.

Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day.

Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?

by Zacks Equity Research

An FDA advisory committee recommended approving Pfizer's (PFE) and GSK's respective RSV vaccines for older adults. Currently, there are no RSV vaccines anywhere in the world.

Glaxo (GSK) Down 1.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $34.58, marking a +0.93% move from the previous day.

The Zacks Analyst Blog Highlights Apple, Linde, Marsh & McLennan Companies, GSK and Expedia

by Zacks Equity Research

Apple, Linde, Marsh & McLennan Companies, GSK and Expedia are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Apple, Linde & Marsh & McLennan

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Linde plc (LIN) and Marsh & McLennan Companies, Inc. (MMC).

Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down

by Zacks Equity Research

Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.

Gilead (GILD) Reports Positive Data From Urothelial Cancer Study

by Zacks Equity Research

Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy

by Zacks Equity Research

Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.

Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology

by Zacks Equity Research

Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.

GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

by Zacks Equity Research

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook

by Zacks Equity Research

GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.

GSK (GSK) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 8.47% and 4.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?